{"Title": ["FDA Nod For EPZM, RARE, Court Rules In MYL's Favor, Ocuphire To Hop Onto Nasdaq, ALPN Soars", "Epizyme's Tazverik Wins FDA Approval to Treat Follicular Lymphoma", "2 Top Cancer Treatment Stocks to Buy in June", "Biotech Stocks Facing FDA Decision In June 2020", "Analysts Expect XBI Will Reach $134", "Epizyme Inc (EPZM) Q1 2020 Earnings Call Transcript", "3 Top Biotech Stocks with FDA Approvals on the Horizon", "Should You Buy These 4 Biotech Stocks With Recent Drug Approvals?", "FDA Nod For EPZM, RARE, Court Rules In MYL's Favor, Ocuphire To Hop Onto Nasdaq, ALPN Soars", "Here's Why Epizyme Lost 27.6% in March", "3 Cancer Treatment Stocks to Buy Right Now", "Epizyme Becomes Oversold (EPZM)", "EPZM Crosses Below Key Moving Average Level", "Smart Money Is Clamoring to Own This Cancer-Fighting Biotech", "Analysts: 3 Healthcare Stocks to Buy on Coronavirus Weakness", "Epizyme Inc (EPZM) Q4 2019 Earnings Call Transcript", "EPZM Crosses Above Key Moving Average Level", "Health Care Sector Update for 02/24/2020: UTHR,GILD,EPZM", "Here's Why Epizyme Is Tumbling Today", "Epizyme's Cancer Drug to Get Rapid FDA Review for a New Indication", "Here's Why Epizyme Is Down on Good News Today", "FDA Approves Epizyme's Sarcoma Drug Tazverik", "First Week of March 20th Options Trading For Epizyme (EPZM)", "The EPZM Paradox: Analysts Bullish But Forecast -13.2% Fall", "Health Care Sector Update for 02/24/2020: NGM,UTHR,GILD,EPZM", "Biotech Stocks Facing FDA Decision In January 2020", "3 Healthcare Stocks With Huge FDA Decisions in January", "Health Care Sector Update for 12/18/2019: EPZM,SYRS,GBT,AXGN,SLDB", "4 Healthcare Stocks With FDA Approvals on the Horizon", "At The ASH 2019 Annual Meeting: AXLA, CBMG, SRRA, EPZM, STOK...", "Health Care Sector Update for 11/04/2019: BNTX,WMGI,EPZM,HALO", "Health Care Sector Update for 11/04/2019: EPZM,WMGI,HALO,SYK", "What Awaits Epizyme (EPZM), Aimmune Therapeutics (AIMT) This Week?", "Epizyme Enters Oversold Territory", "Where Will Epizyme Be in 1 Year?", "First Week of September 20th Options Trading For Epizyme (EPZM)", "Here's Why Epizyme Rose 103.7% in the First Half of 2019", "Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4", "5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings", "Epizyme to File NDA for Tazemetostat in Follicular Lymphoma", "Epizyme (EPZM) Shares Cross Above 200 DMA", "Here's Why Epizyme's Shares Are Surging 19.6% Higher Today", "Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report?", "Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3", "Epizyme (EPZM) Reports Q3 Loss, Lags Revenue Estimates", "Monday 10/8 Insider Buying Report: EPZM, IIPR", "FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study", "Commit To Buy Epizyme At $7.50, Earn 8.3% Annualized Using Options", "Why GameStop, Novavax, and Epizyme Jumped Today", "Here's Why Epizyme's Shares Are Surging 19.6% Higher Today", "Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report?", "Why Is Epizyme (EPZM) Up 16.2% Since Its Last Earnings Report?", "Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1", "Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss", "Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?", "Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks", "Why Is Epizyme (EPZM) Down 18% Since Its Last Earnings Report?", "Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up", "Epizyme Enters Oversold Territory (EPZM)", "Commit To Purchase Epizyme At $15, Earn 17.6% Annualized Using Options", "Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4", "Health Care Sector Update for 03/13/2018: ABBV, BLCM, EPZM, MRK", "Epizyme (EPZM) Reports Narrower-than-Expected Q4 Loss", "Is a Beat in Store for Epizyme (EPZM) This Earnings Season?", "Health Care Sector Update for 03/13/2018: ABBV,NBIX,EPZM,BLCM,MRK", "Health Care Sector Update for 03/13/2018: EPZM,BLCM,MRK", "Pre-Market Earnings Report for March 13, 2018 : HDS, DKS, GDS, DSW, EPZM, NRE, ATRS, MLNT, ARLZ, GNMX, TSQ, GLMD", "Should You Buy Epizyme (EPZM) Ahead of Earnings?", "What's in Store for Epizyme (EPZM) This Earnings Season?", "Stocks Finally Take a Well-Deserved Break", "Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3", "Earnings Reaction History: Epizyme, Inc., 33.3% Follow-Through Indicator, 6.0% Sensitive", "Tuesday 9/19 Insider Buying Report: EPZM, PLUG", "Why Blue Apron Holdings, Tailored Brands, and Epizyme Jumped Today", "Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2", "Epizyme (EPZM) Reports Narrower-than-Expected Q2 Loss", "What to Expect from Epizyme (EPZM) This Earnings Season?", "Epizyme Progressing Well on Two Lead Pipeline Candidates", "What to Expect From Epizyme (EPZM) This Earnings Season?", "No Energy to Follow Through", "Epizyme (EPZM) Jumps: Stock Rises 17.4%", "Epizyme Provides Positive Interim Data on EZH2 Inhibitor", "Why Epizyme Inc.'s Shares Are Skyrocketing Today", "Why Epizyme, Tribune Media, and Revlon Jumped Today", "Midday Update: Soft Retail Sales, CPI Compromises Early Gains; Wall Street's Focus Shifts to FOMC", "Close Update: Dow Sets Record High After Fed Hikes Rates", "Tech Strikes Back", "Epizyme (EPZM) Down 19.2% Since Earnings Report: Can It Rebound?", "Implied Volatility Surging for Epizyme (EPZM) Stock Options", "Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth", "Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q1", "Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss", "3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month", "Noteworthy Wednesday Option Activity: CBS, EPZM, BLL", "Why SeaWorld Entertainment, Brookdale Senior Living, and Epizyme Jumped Today", "Tuesday's ETF Movers: XBI, GDXJ", "Why Epizyme Inc. Shares Are Soaring Today", "Why Is Epizyme (EPZM) Down 3.6% Since the Last Earnings Report?", "10 Small-Cap Stocks That Could Double in the Next 3 Months", "Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus", "Epizyme (EPZM) Reports A Narrower Q4 Loss", "Pre-Market Earnings Report for March 9, 2017 : SPLS, IGT, SIG, ERJ, FMSA, PRTY, BPMC, EGL, SSYS, EPZM, PGNX, GLP", "What to Expect from Epizyme (EPZM) This Earnings Season?", "Tuesday's ETF Movers: XBI, GDXJ", "Why Epizyme Inc. Shares Are Soaring Today", "Why Is Epizyme (EPZM) Down 3.6% Since the Last Earnings Report?", "10 Small-Cap Stocks That Could Double in the Next 3 Months", "AbbVie's HCV Combo Favorable in Japanese Phase III Study", "Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases", "Can Epizyme (EPZM) Spring a Surprise This Earnings Season?", "Pluristem (PSTI) Intermittent Claudication Study Enrolled", "Gilead (GILD) HBV Drug Vemlidy Receives European Approval", "TherapeuticsMD's Rejoice Study Data Published in Journal", "Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU", "Celgene Issues Preliminary 2016 Results, Lifts 2017 View", "AbbVie's HCV Combo Favorable in Japanese Phase III Study", "Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases", "Emergent Down on '17 View, Posts Preliminary '16 Results", "Alexion Blood Disorder Drug Gets Orphan Designation in U.S.", "Vertex Pharma Issues Disappointing 2017 Orkambi Outlook", "Puma (PBYI) Expands Study Cohort for Lead Candidate PB272", "Moving Average Crossover Alert: Epizyme (EPZM)", "Epizyme Tazemetostat Gets Fast Track Designation in U.S.", "Noteworthy Thursday Option Activity: EPZM, SCCO, TREE", "Epizyme (EPZM) Q2 Loss Lower than Expected, Costs to Rise", "Epizyme (EPZM) Posts Narrower-Than-Expected Loss in Q3", "Epizyme (EPZM) Q3 Earnings: What's in Store for the Stock?", "Health Care Sector Update for 09/21/2016: SKLN", "Epizyme Receives Milestone from Glaxo for Lymphoma Drug", "Epizyme Non-Hodgkin Lymphoma Drug Clears Futility Hurdle", "Ronald Muhlenkamp Sells JPMorgan, Morgan Stanley", "Earnings Estimates Moving Higher for Epizyme (EPZM): Time to Buy?", "Friday's ETF Movers: XBI, RHS", "Epizyme (EPZM) Posts Narrower-Than-Expected Loss in Q2", "Monday's ETF Movers: XOP, XBI", "What's in Store for Epizyme (EPZM) this Earnings Season?", "Epizyme Teams Up with Roche's Genentech for Tazemetostat", "Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug", "Ronald Muhlenkamp Sells JPMorgan, Morgan Stanley", "Earnings Estimates Moving Higher for Epizyme (EPZM): Time to Buy?", "Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss", "Why Epizyme (EPZM) Could Be Positioned for a Surge?", "The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics", "Can The Uptrend Continue for Epizyme (EPZM)?", "Epizyme Q4 Loss Narrower than Expected, Pipeline in Focus", "Epizyme (EPZM) Posts Narrower-Than-Expected Loss in Q4", "Pre-Market Earnings Report for March 9, 2016 : CPG, EXPR, KFY, AMED, TRK, VRA, ORBC, EPZM, TRVN, LGIH, HOV, ABDC", "What's in Store for Epizyme (EPZM) this Earnings Season?", "Potential Winners: 3 Small-Cap Stocks Surging this Week", "Why Epizyme (EPZM) Could Be Positioned for a Surge?", "The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics", "Can The Uptrend Continue for Epizyme (EPZM)?", "Epizyme Q4 Loss Narrower than Expected, Pipeline in Focus", "Epizyme (EPZM) Posts Narrower-Than-Expected Loss in Q4", "Pre-Market Earnings Report for March 9, 2016 : CPG, EXPR, KFY, AMED, TRK, VRA, ORBC, EPZM, TRVN, LGIH, HOV, ABDC", "What's in Store for Epizyme (EPZM) this Earnings Season?", "Potential Winners: 3 Small-Cap Stocks Surging this Week", "Epizyme's Tazemetostat Gets Orphan Drug Status in the U.S.", "Pre-Market Most Active for Jan 7, 2016 : TVIX, XIV, ATML, QQQ, SUNE, AAPL, BP, BAC, EPZM, FCX, YZC, AA", "Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today", "Thursday's ETF Movers: GDX, XBI", "Epizyme Initiates Dosing in Phase II Study on Tazemetostat", "Health Care Sector Update for 12/30/2015: KMPH, EPZM", "Epizyme's Tazemetostat IND Application Accepted for DLBCL", "Peek Under The Hood: VB Has 29% Upside", "Epizyme Updates Non-Hodgkin Lymphoma Drug Trial Data", "Epizyme's Q3 Loss Wider-Than-Expected, Pipeline in Focus", "Epizyme (EPZM) Posts Wider-Than-Expected Loss in Q3", "Will Epizyme (EPZM) Disappoint This Earnings Season?", "Monday Sector Laggards: Drugs, Biotechnology Stocks", "Epizyme (EPZM) Shows Strength: Stock Adds 9.6% in Session", "Epizyme (EPZM) Gains as Oncology Candidate Advances", "Health Care Sector Update for 12/28/2015: IMNP, EPZM", "What's in Store for Evogene (EVGN) this Earnings Season? - Analyst Blog", "Can Mallinckrodt (MNK) Keep The Earnings Streak Alive? - Analyst Blog", "What's in Store for Aegerion (AEGR) This Earnings Season? - Analyst Blog", "Will Endocyte (ECYT) Earnings Surprise Investors in Q2? - Analyst Blog", "Epizyme/Celgene Extend Research Deal for HMT Inhibitors - Analyst Blog", "The Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases", "Will Radius Health (RDUS) Disappoint This Earnings Season? - Analyst Blog", "Intercept Pharmaceuticals (ICPT): Q2 Earnings Preview - Analyst Blog", "What's in Store for Evogene (EVGN) this Earnings Season? - Analyst Blog", "Can Mallinckrodt (MNK) Keep The Earnings Streak Alive? - Analyst Blog", "What's in Store for Aegerion (AEGR) This Earnings Season? - Analyst Blog", "Will Epizyme (EPZM) Beat Estimates This Earnings Season? - Analyst Blog", "Epizyme (EPZM) Crumbles: Stock Falls by 9.6% - Tale of the Tape", "Epizyme's Loss Narrower than Expected, Focus on Pipeline - Analyst Blog", "Epizyme (EPZM) Shows Strength: Stock Moves 25.2% Higher - Tale of the Tape", "Epizyme Lead Candidate Effective in Ongoing Cancer Study - Analyst Blog", "Monday Sector Leaders: Drugs, Real Estate Stocks", "Why Epizyme Inc. Shares Are Soaring", "Should You Sell Epizyme (EPZM) Before Earnings? - Tale of the Tape", "Will Epizyme (EPZM) Beat Estimates This Earnings Season? - Analyst Blog", "Epizyme (EPZM) Crumbles: Stock Falls by 9.6% - Tale of the Tape", "Epizyme's Loss Narrower than Expected, Focus on Pipeline - Analyst Blog", "Epizyme (EPZM) Shows Strength: Stock Moves 25.2% Higher - Tale of the Tape", "Health Care Sector Update for 03/12/2015: ATRS, MD, EPZM", "Epizyme (EPZM) Posts Narrower-than-Expected Loss in Q4 - Tale of the Tape", "Pre-Market Earnings Report for March 12, 2015 : DG, LEAF, MTN, RICE, CMN, GCO, PLCE, GLP, PGEM, PWE, EPZM, TLP", "Will Epizyme (EPZM) Miss Estimates This Earnings Season? - Analyst Blog", "3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't", "Epizyme Gains on Positive Phase I Data on EPZ-6438 - Analyst Blog", "Can Epizyme (EPZM) Surprise This Earnings Season? - Analyst Blog", "Company News for March 13, 2015 - Corporate Summary", "Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape", "Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape", "Vical Incorporated (VICL) in Focus: Stock Soars 12% - Tale of the Tape", "Commit To Purchase Epizyme At $22.50, Earn 19.4% Annualized Using Options", "Why Epizyme (EPZM) Stock Might be a Great Pick - Tale of the Tape", "Monday Sector Leaders: Biotechnology, Drugs", "Bull of the Day: Epizyme (EPZM) - Bull of the Day", "What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape", "Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape", "Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape", "Vical Incorporated (VICL) in Focus: Stock Soars 12% - Tale of the Tape", "Epizyme Up on Milestone Payment from Glaxo - Analyst Blog", "Biopharmaceutical company Epizyme sets terms for $60 million IPO", "Epizyme files for a $69 million IPO", "Company News for June 3, 2013 - Corporate Summary"], "Elapsed Time": ["JUN 19, 2020", "JUN 18, 2020", "JUN 16, 2020", "MAY 26, 2020", "MAY 15, 2020", "MAY 4, 2020", "APR 19, 2020", "APR 15, 2020", "JUN 19, 2020", "APR 6, 2020", "MAR 19, 2020", "MAR 13, 2020", "MAR 13, 2020", "MAR 9, 2020", "FEB 25, 2020", "FEB 24, 2020", "APR 8, 2020", "FEB 24, 2020", "FEB 24, 2020", "FEB 14, 2020", "JAN 24, 2020", "JAN 23, 2020", "JAN 23, 2020", "JAN 23, 2020", "FEB 24, 2020", "DEC 31, 2019", "DEC 30, 2019", "DEC 18, 2019", "DEC 12, 2019", "DEC 8, 2019", "NOV 4, 2019", "NOV 4, 2019", "JAN 21, 2020", "OCT 1, 2019", "SEP 5, 2019", "JUL 24, 2019", "JUL 12, 2019", "FEB 27, 2019", "FEB 14, 2019", "JAN 7, 2019", "NOV 4, 2019", "JAN 4, 2019", "DEC 2, 2018", "NOV 5, 2018", "NOV 2, 2018", "OCT 8, 2018", "SEP 25, 2018", "SEP 24, 2018", "JAN 4, 2019", "JAN 4, 2019", "DEC 2, 2018", "JUN 7, 2018", "MAY 9, 2018", "MAY 8, 2018", "MAY 7, 2018", "AUG 3, 2018", "APR 12, 2018", "APR 11, 2018", "APR 6, 2018", "MAR 26, 2018", "MAR 14, 2018", "MAR 13, 2018", "MAR 13, 2018", "MAY 7, 2018", "MAR 13, 2018", "MAR 13, 2018", "MAR 12, 2018", "MAR 9, 2018", "FEB 27, 2018", "JAN 11, 2018", "NOV 2, 2017", "MAR 13, 2018", "SEP 19, 2017", "SEP 15, 2017", "AUG 7, 2017", "AUG 4, 2017", "AUG 1, 2017", "JUN 26, 2017", "OCT 27, 2017", "JUN 21, 2017", "JUN 16, 2017", "JUN 15, 2017", "JUN 15, 2017", "JUN 15, 2017", "JUN 14, 2017", "JUN 14, 2017", "JUN 26, 2017", "JUN 13, 2017", "MAY 18, 2017", "MAY 17, 2017", "MAY 9, 2017", "MAY 8, 2017", "MAY 5, 2017", "MAY 3, 2017", "JUN 14, 2017", "APR 25, 2017", "APR 25, 2017", "APR 10, 2017", "MAR 21, 2017", "MAR 10, 2017", "MAR 9, 2017", "MAR 8, 2017", "MAY 3, 2017", "APR 25, 2017", "APR 25, 2017", "APR 10, 2017", "MAR 21, 2017", "JAN 10, 2017", "JAN 10, 2017", "MAR 6, 2017", "JAN 13, 2017", "JAN 12, 2017", "JAN 12, 2017", "JAN 11, 2017", "JAN 10, 2017", "JAN 10, 2017", "NOV 4, 2016", "JAN 10, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "DEC 19, 2016", "NOV 29, 2016", "NOV 10, 2016", "AUG 9, 2016", "NOV 3, 2016", "NOV 1, 2016", "SEP 21, 2016", "SEP 16, 2016", "JUN 20, 2016", "JUN 16, 2016", "JUN 9, 2016", "MAY 20, 2016", "AUG 8, 2016", "AUG 8, 2016", "AUG 3, 2016", "JUN 23, 2016", "JUN 20, 2016", "JUN 16, 2016", "JUN 9, 2016", "MAY 10, 2016", "MAR 31, 2016", "MAR 29, 2016", "MAR 21, 2016", "MAR 10, 2016", "MAR 9, 2016", "MAR 8, 2016", "MAR 7, 2016", "APR 6, 2016", "MAR 31, 2016", "MAR 29, 2016", "MAR 21, 2016", "MAR 10, 2016", "MAR 9, 2016", "MAR 8, 2016", "MAR 7, 2016", "APR 6, 2016", "FEB 9, 2016", "JAN 7, 2016", "JAN 7, 2016", "JAN 7, 2016", "DEC 31, 2015", "DEC 30, 2015", "DEC 29, 2015", "FEB 11, 2016", "DEC 8, 2015", "NOV 10, 2015", "NOV 9, 2015", "NOV 2, 2015", "SEP 28, 2015", "AUG 25, 2015", "AUG 25, 2015", "DEC 28, 2015", "AUG 3, 2015", "AUG 3, 2015", "AUG 3, 2015", "AUG 3, 2015", "JUL 10, 2015", "JUN 25, 2015", "AUG 4, 2015", "AUG 4, 2015", "AUG 3, 2015", "AUG 3, 2015", "AUG 3, 2015", "APR 27, 2015", "MAR 16, 2015", "MAR 13, 2015", "JUN 23, 2015", "JUN 22, 2015", "JUN 22, 2015", "JUN 22, 2015", "APR 27, 2015", "APR 27, 2015", "MAR 16, 2015", "MAR 13, 2015", "JUN 23, 2015", "MAR 12, 2015", "MAR 12, 2015", "MAR 11, 2015", "FEB 25, 2015", "DEC 7, 2014", "NOV 21, 2014", "OCT 24, 2014", "MAR 13, 2015", "OCT 14, 2014", "OCT 14, 2014", "OCT 14, 2014", "OCT 1, 2014", "SEP 10, 2014", "AUG 25, 2014", "AUG 22, 2014", "OCT 17, 2014", "OCT 14, 2014", "OCT 14, 2014", "OCT 14, 2014", "APR 23, 2014", "MAY 21, 2013", "APR 18, 2013", "JUN 3, 2013"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/fda-nod-for-epzm-rare-court-rules-in-myls-favor-ocuphire-to-hop-onto-nasdaq-alpn-soars", "https://www.nasdaq.com/articles/epizymes-tazverik-wins-fda-approval-to-treat-follicular-lymphoma-2020-06-18", "https://www.nasdaq.com/articles/2-top-cancer-treatment-stocks-to-buy-in-june-2020-06-16", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-june-2020-2020-05-26", "https://www.nasdaq.com/articles/analysts-expect-xbi-will-reach-%24134-2020-05-15", "https://www.nasdaq.com/articles/epizyme-inc-epzm-q1-2020-earnings-call-transcript-2020-05-04", "https://www.nasdaq.com/articles/3-top-biotech-stocks-with-fda-approvals-on-the-horizon-2020-04-19", "https://www.nasdaq.com/articles/should-you-buy-these-4-biotech-stocks-with-recent-drug-approvals-2020-04-15", "https://www.nasdaq.com/articles/fda-nod-for-epzm-rare-court-rules-in-myls-favor-ocuphire-to-hop-onto-nasdaq-alpn-soars", "https://www.nasdaq.com/articles/heres-why-epizyme-lost-27.6-in-march-2020-04-06", "https://www.nasdaq.com/articles/3-cancer-treatment-stocks-to-buy-right-now-2020-03-19", "https://www.nasdaq.com/articles/epizyme-becomes-oversold-epzm-2020-03-13", "https://www.nasdaq.com/articles/epzm-crosses-below-key-moving-average-level-2020-03-13", "https://www.nasdaq.com/articles/smart-money-is-clamoring-to-own-this-cancer-fighting-biotech-2020-03-09", "https://www.nasdaq.com/articles/analysts%3A-3-healthcare-stocks-to-buy-on-coronavirus-weakness-2020-02-25", "https://www.nasdaq.com/articles/epizyme-inc-epzm-q4-2019-earnings-call-transcript-2020-02-24", "https://www.nasdaq.com/articles/epzm-crosses-above-key-moving-average-level-2020-04-08", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-24-2020%3A-uthrgildepzm-2020-02-24", "https://www.nasdaq.com/articles/heres-why-epizyme-is-tumbling-today-2020-02-24", "https://www.nasdaq.com/articles/epizymes-cancer-drug-to-get-rapid-fda-review-for-a-new-indication-2020-02-14", "https://www.nasdaq.com/articles/heres-why-epizyme-is-down-on-good-news-today-2020-01-24", "https://www.nasdaq.com/articles/fda-approves-epizymes-sarcoma-drug-tazverik-2020-01-24", "https://www.nasdaq.com/articles/first-week-of-march-20th-options-trading-for-epizyme-epzm-2020-01-23", "https://www.nasdaq.com/articles/the-epzm-paradox%3A-analysts-bullish-but-forecast-13.2-fall-2020-01-23", "https://www.nasdaq.com/articles/health-care-sector-update-for-02-24-2020%3A-ngmuthrgildepzm-2020-02-24", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-january-2020-2019-12-31", "https://www.nasdaq.com/articles/3-healthcare-stocks-with-huge-fda-decisions-in-january-2019-12-30", "https://www.nasdaq.com/articles/health-care-sector-update-for-12-18-2019%3A-epzmsyrsgbtaxgnsldb-2019-12-18", "https://www.nasdaq.com/articles/4-healthcare-stocks-with-fda-approvals-on-the-horizon-2019-12-12", "https://www.nasdaq.com/articles/at-the-ash-2019-annual-meeting%3A-axla-cbmg-srra-epzm-stok...-2019-12-08", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-04-2019%3A-bntxwmgiepzmhalo-2019-11-04", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-04-2019%3A-epzmwmgihalosyk-2019-11-04", "https://www.nasdaq.com/articles/what-awaits-epizyme-epzm-aimmune-therapeutics-aimt-this-week-2020-01-21", "https://www.nasdaq.com/articles/epizyme-enters-oversold-territory-2019-10-01", "https://www.nasdaq.com/articles/where-will-epizyme-be-in-1-year-2019-09-05", "https://www.nasdaq.com/articles/first-week-of-september-20th-options-trading-for-epizyme-epzm-2019-07-24", "https://www.nasdaq.com/articles/heres-why-epizyme-rose-103.7-in-the-first-half-of-2019-2019-07-12", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q4-2019-02-27", "https://www.nasdaq.com/articles/5-drug-biotech-stocks-set-to-beat-estimates-in-q4-earnings-2019-02-14", "https://www.nasdaq.com/articles/epizyme-to-file-nda-for-tazemetostat-in-follicular-lymphoma-2019-01-07", "https://www.nasdaq.com/articles/epizyme-epzm-shares-cross-above-200-dma-2019-11-04", "https://www.nasdaq.com/articles/heres-why-epizymes-shares-are-surging-196-higher-today-2019-01-04", "https://www.nasdaq.com/articles/why-is-epizyme-epzm-down-11.9-since-last-earnings-report-2018-12-02", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q3-2018-11-05", "https://www.nasdaq.com/articles/epizyme-epzm-reports-q3-loss-lags-revenue-estimates-2018-11-02", "https://www.nasdaq.com/articles/monday-108-insider-buying-report-epzm-iipr-2018-10-08", "https://www.nasdaq.com/articles/fda-lifts-clinical-hold-on-epizymes-lead-candidates-study-2018-09-25", "https://www.nasdaq.com/articles/commit-buy-epizyme-750-earn-83-annualized-using-options-2018-09-24", "https://www.nasdaq.com/articles/why-gamestop-novavax-and-epizyme-jumped-today-2019-01-04", "https://www.nasdaq.com/articles/heres-why-epizymes-shares-are-surging-196-higher-today-2019-01-04", "https://www.nasdaq.com/articles/why-is-epizyme-epzm-down-11.9-since-last-earnings-report-2018-12-02", "https://www.nasdaq.com/articles/why-is-epizyme-epzm-up-16.2-since-its-last-earnings-report-2018-06-07", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q1-2018-05-09", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-q1-loss-2018-05-08", "https://www.nasdaq.com/articles/puma-biotech-pbyi-to-report-q1-earnings%3A-what-to-expect-2018-05-07", "https://www.nasdaq.com/articles/epizyme-epzm-q2-loss-narrows-shares-crash-24-on-setbacks-2018-08-03", "https://www.nasdaq.com/articles/why-is-epizyme-epzm-down-18-since-its-last-earnings-report-2018-04-12", "https://www.nasdaq.com/articles/epizyme-epzm-publishes-tazemetostat-phase-i-data-stock-up-2018-04-11", "https://www.nasdaq.com/articles/epizyme-enters-oversold-territory-epzm-2018-04-06", "https://www.nasdaq.com/articles/commit-purchase-epizyme-15-earn-176-annualized-using-options-2018-03-26", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q4-2018-03-14", "https://www.nasdaq.com/articles/health-care-sector-update-03132018-abbv-blcm-epzm-mrk-2018-03-13", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-q4-loss-2018-03-13", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-epizyme-epzm-this-earnings-season-2018-05-07", "https://www.nasdaq.com/articles/health-care-sector-update-03132018-abbvnbixepzmblcmmrk-2018-03-13", "https://www.nasdaq.com/articles/health-care-sector-update-03132018-epzmblcmmrk-2018-03-13", "https://www.nasdaq.com/articles/pre-market-earnings-report-march-13-2018-hds-dks-gds-dsw-epzm-nre-atrs-mlnt-arlz-gnmx-tsq", "https://www.nasdaq.com/articles/should-you-buy-epizyme-epzm-ahead-of-earnings-2018-03-09", "https://www.nasdaq.com/articles/whats-in-store-for-epizyme-epzm-this-earnings-season-2018-02-27", "https://www.nasdaq.com/articles/stocks-finally-take-well-deserved-break-2018-01-11", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q3-2017-11-02", "https://www.nasdaq.com/articles/earnings-reaction-history-epizyme-inc-333-follow-through-indicator-60-sensitive-2018-03-13", "https://www.nasdaq.com/articles/tuesday-919-insider-buying-report-epzm-plug-2017-09-19", "https://www.nasdaq.com/articles/why-blue-apron-holdings-tailored-brands-and-epizyme-jumped-today-2017-09-15", "https://www.nasdaq.com/articles/epizyme-epzm-incurs-narrower-than-expected-loss-in-q2-2017-08-07", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-q2-loss-2017-08-04", "https://www.nasdaq.com/articles/what-to-expect-from-epizyme-epzm-this-earnings-season-2017-08-01", "https://www.nasdaq.com/articles/epizyme-progressing-well-on-two-lead-pipeline-candidates-2017-06-26", "https://www.nasdaq.com/articles/what-to-expect-from-epizyme-epzm-this-earnings-season-2017-10-27", "https://www.nasdaq.com/articles/no-energy-follow-through-2017-06-21", "https://www.nasdaq.com/articles/epizyme-epzm-jumps%3A-stock-rises-17.4-2017-06-16", "https://www.nasdaq.com/articles/epizyme-provides-positive-interim-data-on-ezh2-inhibitor-2017-06-15", "https://www.nasdaq.com/articles/why-epizyme-incs-shares-are-skyrocketing-today-2017-06-15", "https://www.nasdaq.com/articles/why-epizyme-tribune-media-and-revlon-jumped-today-2017-06-15", "https://www.nasdaq.com/articles/midday-update-soft-retail-sales-cpi-compromises-early-gains-wall-streets-focus-shifts-fomc", "https://www.nasdaq.com/articles/close-update-dow-sets-record-high-after-fed-hikes-rates-2017-06-14", "https://www.nasdaq.com/articles/tech-strikes-back-2017-06-26", "https://www.nasdaq.com/articles/epizyme-epzm-down-19.2-since-earnings-report%3A-can-it-rebound-2017-06-13", "https://www.nasdaq.com/articles/implied-volatility-surging-for-epizyme-epzm-stock-options-2017-05-18", "https://www.nasdaq.com/articles/orexigen-orex-obesity-drug-contrave-registers-slow-growth-2017-05-17", "https://www.nasdaq.com/articles/epizyme-epzm-incurs-narrower-than-expected-loss-in-q1-2017-05-09", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-expected-q1-loss-2017-05-08", "https://www.nasdaq.com/articles/3-intriguing-cancer-drugs-data-coming-asco-next-month-2017-05-05", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-cbs-epzm-bll-2017-05-03", "https://www.nasdaq.com/articles/why-seaworld-entertainment-brookdale-senior-living-and-epizyme-jumped-today-2017-06-14", "https://www.nasdaq.com/articles/tuesdays-etf-movers-xbi-gdxj-2017-04-25", "https://www.nasdaq.com/articles/why-epizyme-inc-shares-are-soaring-today-2017-04-25", "https://www.nasdaq.com/articles/why-is-epizyme-epzm-down-3.6-since-the-last-earnings-report-2017-04-10", "https://www.nasdaq.com/articles/10-small-cap-stocks-that-could-double-in-the-next-3-months-2017-03-21", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-q4-loss-pipeline-in-focus-2017-03-10", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-q4-loss-2017-03-09", "https://www.nasdaq.com/articles/pre-market-earnings-report-march-9-2017-spls-igt-sig-erj-fmsa-prty-bpmc-egl-ssys-epzm-pgnx", "https://www.nasdaq.com/articles/what-to-expect-from-epizyme-epzm-this-earnings-season-2017-05-03", "https://www.nasdaq.com/articles/tuesdays-etf-movers-xbi-gdxj-2017-04-25", "https://www.nasdaq.com/articles/why-epizyme-inc-shares-are-soaring-today-2017-04-25", "https://www.nasdaq.com/articles/why-is-epizyme-epzm-down-3.6-since-the-last-earnings-report-2017-04-10", "https://www.nasdaq.com/articles/10-small-cap-stocks-that-could-double-in-the-next-3-months-2017-03-21", "https://www.nasdaq.com/articles/abbvies-hcv-combo-favorable-in-japanese-phase-iii-study-2017-01-10", "https://www.nasdaq.com/articles/sanofi-immunext-ink-deal-focus-on-autoimmune-diseases-2017-01-10", "https://www.nasdaq.com/articles/can-epizyme-epzm-spring-a-surprise-this-earnings-season-2017-03-06", "https://www.nasdaq.com/articles/pluristem-psti-intermittent-claudication-study-enrolled-2017-01-13", "https://www.nasdaq.com/articles/gilead-gild-hbv-drug-vemlidy-receives-european-approval-2017-01-12", "https://www.nasdaq.com/articles/therapeuticsmds-rejoice-study-data-published-in-journal-2017-01-12", "https://www.nasdaq.com/articles/alexion-alxn-files-for-label-expansion-of-soliris-in-u.s.-eu-2017-01-11", "https://www.nasdaq.com/articles/celgene-issues-preliminary-2016-results-lifts-2017-view-2017-01-10", "https://www.nasdaq.com/articles/abbvies-hcv-combo-favorable-in-japanese-phase-iii-study-2017-01-10", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-than-expected-loss-in-q3-2016-11-04", "https://www.nasdaq.com/articles/emergent-down-on-17-view-posts-preliminary-16-results-2017-01-10", "https://www.nasdaq.com/articles/alexion-blood-disorder-drug-gets-orphan-designation-in-u.s.-2017-01-09", "https://www.nasdaq.com/articles/vertex-pharma-issues-disappointing-2017-orkambi-outlook-2017-01-09", "https://www.nasdaq.com/articles/puma-pbyi-expands-study-cohort-for-lead-candidate-pb272-2017-01-09", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-epizyme-epzm-2016-12-19", "https://www.nasdaq.com/articles/epizyme-tazemetostat-gets-fast-track-designation-in-u.s.-2016-11-29", "https://www.nasdaq.com/articles/epizyme-doses-first-patient-in-phase-ii-mesothelioma-study-2016-08-15", "https://www.nasdaq.com/articles/epizyme-epzm-q2-loss-lower-than-expected-costs-to-rise-2016-08-09", "https://www.nasdaq.com/articles/epizyme-epzm-posts-narrower-than-expected-loss-in-q3-2016-11-03", "https://www.nasdaq.com/articles/epizyme-epzm-q3-earnings%3A-whats-in-store-for-the-stock-2016-11-01", "https://www.nasdaq.com/articles/health-care-sector-update-09212016-skln-2016-09-21", "https://www.nasdaq.com/articles/epizyme-receives-milestone-from-glaxo-for-lymphoma-drug-2016-09-16", "https://www.nasdaq.com/articles/epizyme-offers-early-data-on-non-hodgkin-lymphoma-drug-2016-06-20", "https://www.nasdaq.com/articles/ronald-muhlenkamp-sells-jpmorgan-morgan-stanley-2016-06-16", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-epizyme-epzm%3A-time-to-buy-2016-06-09", "https://www.nasdaq.com/articles/fridays-etf-movers-xbi-rhs-2016-05-20", "https://www.nasdaq.com/articles/epizyme-epzm-posts-narrower-than-expected-loss-in-q2-2016-08-08", "https://www.nasdaq.com/articles/mondays-etf-movers-xop-xbi-2016-08-08", "https://www.nasdaq.com/articles/whats-in-store-for-epizyme-epzm-this-earnings-season-2016-08-03", "https://www.nasdaq.com/articles/epizyme-teams-up-with-roches-genentech-for-tazemetostat-2016-06-23", "https://www.nasdaq.com/articles/epizyme-offers-early-data-on-non-hodgkin-lymphoma-drug-2016-06-20", "https://www.nasdaq.com/articles/ronald-muhlenkamp-sells-jpmorgan-morgan-stanley-2016-06-16", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-epizyme-epzm%3A-time-to-buy-2016-06-09", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-expected-q1-loss-2016-05-10", "https://www.nasdaq.com/articles/why-epizyme-epzm-could-be-positioned-for-a-surge-2016-03-31", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-corcept-therapeutics-epizyme-geron-and-synthetic", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-epizyme-epzm-2016-03-21", "https://www.nasdaq.com/articles/epizyme-q4-loss-narrower-than-expected-pipeline-in-focus-2016-03-10", "https://www.nasdaq.com/articles/epizyme-epzm-posts-narrower-expected-loss-q4-2016-03-09", "https://www.nasdaq.com/articles/pre-market-earnings-report-march-9-2016-cpg-expr-kfy-amed-trk-vra-orbc-epzm-trvn-lgih-hov", "https://www.nasdaq.com/articles/whats-in-store-for-epizyme-epzm-this-earnings-season-2016-03-07", "https://www.nasdaq.com/articles/potential-winners-3-small-cap-stocks-surging-week-2016-04-06", "https://www.nasdaq.com/articles/why-epizyme-epzm-could-be-positioned-for-a-surge-2016-03-31", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-corcept-therapeutics-epizyme-geron-and-synthetic", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-epizyme-epzm-2016-03-21", "https://www.nasdaq.com/articles/epizyme-q4-loss-narrower-than-expected-pipeline-in-focus-2016-03-10", "https://www.nasdaq.com/articles/epizyme-epzm-posts-narrower-expected-loss-q4-2016-03-09", "https://www.nasdaq.com/articles/pre-market-earnings-report-march-9-2016-cpg-expr-kfy-amed-trk-vra-orbc-epzm-trvn-lgih-hov", "https://www.nasdaq.com/articles/whats-in-store-for-epizyme-epzm-this-earnings-season-2016-03-07", "https://www.nasdaq.com/articles/potential-winners-3-small-cap-stocks-surging-week-2016-04-06", "https://www.nasdaq.com/articles/epizymes-tazemetostat-gets-orphan-drug-status-in-the-u.s.-2016-02-09", "https://www.nasdaq.com/articles/pre-market-most-active-jan-7-2016-tvix-xiv-atml-qqq-sune-aapl-bp-bac-epzm-fcx-yzc-aa-2016", "https://www.nasdaq.com/articles/why-epizyme-inc-akebia-therapeutics-inc-and-cempra-inc-got-wacked-today-2016-01-07", "https://www.nasdaq.com/articles/thursdays-etf-movers-gdx-xbi-2016-01-07", "https://www.nasdaq.com/articles/epizyme-initiates-dosing-in-phase-ii-study-on-tazemetostat-2015-12-31", "https://www.nasdaq.com/articles/health-care-sector-update-12302015-kmph-epzm-2015-12-30", "https://www.nasdaq.com/articles/epizymes-tazemetostat-ind-application-accepted-for-dlbcl-2015-12-29", "https://www.nasdaq.com/articles/peek-under-hood-vb-has-29-upside-2016-02-11", "https://www.nasdaq.com/articles/epizyme-updates-non-hodgkin-lymphoma-drug-trial-data-2015-12-08", "https://www.nasdaq.com/articles/epizymes-q3-loss-wider-than-expected-pipeline-in-focus-2015-11-10", "https://www.nasdaq.com/articles/epizyme-epzm-posts-wider-than-expected-loss-in-q3-2015-11-09", "https://www.nasdaq.com/articles/will-epizyme-epzm-disappoint-this-earnings-season-2015-11-02", "https://www.nasdaq.com/articles/monday-sector-laggards-drugs-biotechnology-stocks-2015-09-28", "https://www.nasdaq.com/articles/epizyme-epzm-shows-strength%3A-stock-adds-9.6-in-session-2015-08-25", "https://www.nasdaq.com/articles/epizyme-epzm-gains-as-oncology-candidate-advances-2015-08-25", "https://www.nasdaq.com/articles/health-care-sector-update-12282015-imnp-epzm-2015-12-28", "https://www.nasdaq.com/articles/whats-in-store-for-evogene-evgn-this-earnings-season-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/can-mallinckrodt-mnk-keep-the-earnings-streak-alive-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/whats-in-store-for-aegerion-aegr-this-earnings-season-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/will-endocyte-ecyt-earnings-surprise-investors-in-q2-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/epizyme-celgene-extend-research-deal-for-hmt-inhibitors-analyst-blog-2015-07-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biomarin-vical-epizyme-amgen-and-medicines-co-press", "https://www.nasdaq.com/articles/will-radius-health-rdus-disappoint-this-earnings-season-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-icpt%3A-q2-earnings-preview-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/whats-in-store-for-evogene-evgn-this-earnings-season-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/can-mallinckrodt-mnk-keep-the-earnings-streak-alive-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/should-you-sell-epizyme-epzm-before-earnings-tale-of-the-tape-2015-04-27", "https://www.nasdaq.com/articles/will-epizyme-epzm-beat-estimates-this-earnings-season-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/epizyme-epzm-crumbles%3A-stock-falls-by-9.6-tale-of-the-tape-2015-03-16", "https://www.nasdaq.com/articles/epizymes-loss-narrower-than-expected-focus-on-pipeline-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/epizyme-epzm-shows-strength%3A-stock-moves-25.2-higher-tale-of-the-tape-2015-06-23", "https://www.nasdaq.com/articles/epizyme-lead-candidate-effective-in-ongoing-cancer-study-analyst-blog-2015-06-22", "https://www.nasdaq.com/articles/monday-sector-leaders-drugs-real-estate-stocks-2015-06-22", "https://www.nasdaq.com/articles/why-epizyme-inc-shares-are-soaring-2015-06-22", "https://www.nasdaq.com/articles/should-you-sell-epizyme-epzm-before-earnings-tale-of-the-tape-2015-04-27", "https://www.nasdaq.com/articles/will-epizyme-epzm-beat-estimates-this-earnings-season-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/epizyme-epzm-crumbles%3A-stock-falls-by-9.6-tale-of-the-tape-2015-03-16", "https://www.nasdaq.com/articles/epizymes-loss-narrower-than-expected-focus-on-pipeline-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/epizyme-epzm-shows-strength%3A-stock-moves-25.2-higher-tale-of-the-tape-2015-06-23", "https://www.nasdaq.com/articles/health-care-sector-update-03122015-atrs-md-epzm-2015-03-12", "https://www.nasdaq.com/articles/epizyme-epzm-posts-narrower-than-expected-loss-in-q4-tale-of-the-tape-2015-03-12", "https://www.nasdaq.com/articles/pre-market-earnings-report-march-12-2015-dg-leaf-mtn-rice-cmn-gco-plce-glp-pgem-pwe-epzm", "https://www.nasdaq.com/articles/will-epizyme-epzm-miss-estimates-this-earnings-season-analyst-blog-2015-02-25", "https://www.nasdaq.com/articles/3-large-cap-biotech-stocks-could-pay-dividends-wont-2014-12-07", "https://www.nasdaq.com/articles/epizyme-gains-on-positive-phase-i-data-on-epz-6438-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/can-epizyme-epzm-surprise-this-earnings-season-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/company-news-for-march-13-2015-corporate-summary-2015-03-13", "https://www.nasdaq.com/articles/protalix-biotherapeutics-inc.-plx-in-focus%3A-stock-surges-11.4-tale-of-the-tape-2014-10-14", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-jumps%3A-stock-rises-19-tale-of-the-tape-2014-10-14", "https://www.nasdaq.com/articles/vical-incorporated-vicl-in-focus%3A-stock-soars-12-tale-of-the-tape-2014-10-14", "https://www.nasdaq.com/articles/commit-purchase-epizyme-2250-earn-194-annualized-using-options-2014-10-01", "https://www.nasdaq.com/articles/why-epizyme-epzm-stock-might-be-a-great-pick-tale-of-the-tape-2014-09-10", "https://www.nasdaq.com/articles/monday-sector-leaders-biotechnology-drugs-2014-08-25", "https://www.nasdaq.com/articles/bull-day-epizyme-epzm-bull-day-2014-08-22", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-enzo-biochem-enz-tale-of-the-tape-2014-10-17", "https://www.nasdaq.com/articles/protalix-biotherapeutics-inc.-plx-in-focus%3A-stock-surges-11.4-tale-of-the-tape-2014-10-14", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-jumps%3A-stock-rises-19-tale-of-the-tape-2014-10-14", "https://www.nasdaq.com/articles/pre-market-earnings-report-august-13-2014-de-m-pf-cae-ioc-seas-ait-csiq-epzm-ezch-wlh-caas", "https://www.nasdaq.com/articles/epizyme-up-on-milestone-payment-from-glaxo-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/biopharmaceutical-company-epizyme-sets-terms-60-million-ipo-2013-05-21", "https://www.nasdaq.com/articles/epizyme-files-69-million-ipo-2013-04-18", "https://www.nasdaq.com/articles/company-news-for-june-3-2013-corporate-summary-2013-06-03"], "Content": []}